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Background: Data on prevalence rates of venous thromboembolism (VTE) in different patient populations
are scarce. Most studies on this topic focus on older patients or patients with malignancies, immobilization
or thrombophilia. Less is known about the VTE risk profile of non-surgical patients presenting with a variety
of medical diseases of differing severity. Aim of the present study was to investigate VTE prevalence in a
pospective cohort study of ambulatory medical intensive care unit patients within 24 h after acute
admission.
Methods: Prospective cohort study of 102 consecutive patients after acute admission to medical intensive
care unit. Ultrasound compression sonography, APACHE-II-Scoring and laboratory examination was
performed within 24 hours after admission.Possible determinants of a high risk of VTE were examined. In all
patients with a confirmed diagnosis of DVT or suspicion of PE thoracic computer tomography (CT) was
performed.
Results: VTE was found in 7.8% out of 102 of patients, mean APACHE-II-Score was 14 (mortality risk of
about 15%). Thrombus location was femoropopliteal in 5 patients, iliacal in 2 and peroneal in 1 patient. Five
VTE patients had concomitant PE (62.5% of VTE, 4.9% of all patients). No predictors of prevalent VTE were
identified from univariable regression analysis although relative risk was high in patients with a history of
smoking (RR 3.40), immobility (RR 2.50), and elevated D-Dimer levels (RR 3.49).
Conclusions: Prevalent VTE and concomitant PE were frequent in acutely admitted ICU patients.
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Venous thromboembolism (VTE) is a common compli-
cation not only in surgical but also in acutely ill hos-
pitalized medical patients [1]. A number of risk factors
have been identified in medical patients resulting in an
increase in VTE rates and mortality. Higher age, cancer,
immobilization, infectious disease, and a history of VTE
[2-5] are amongst the most important ones, as we know
from the large randomized, double-masked, placebo-
controlled MEDENOX Study. Multiple logistic regression
analysis indicated that these factors were independently* Correspondence: h.lawall@asklepios.com
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unless otherwise stated.associated with VTE in the study population of acute
hospitalized patients with heart or respiratory failure, in-
fections, rheumatic disorder or inflammatory bowel dis-
ease [6]. Inherited thrombophilia is another established
risk factor of VTE. A systematic review and meta-analysis
of the prevalence of Factor V Leiden mutation (FVL) and
prothrombin mutation (G20210A) (PTM) found those risk
factors significantly more often in patients with isolated
PE than in controls without VTE (OR 2.06, 95% CI 1.66-
2.56, p < 0,0001 for FVL; OR 2.64, 95% CI 1.92-3.63,
p < 0.0001 for PTM) [7].
Only a small proportion of those medical at-risk patients
are given prophylaxis [2]. Furthermore data show a correl-
ation between mortality and risk score of the patients forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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prophylaxis [9].
Among medical patients, those admitted to an Intensive
Care Unit (ICU) represent a high risk population for VTE
[10-13] with a higher prevalence of the aforementioned
risk factors. The Asian VOICE study detected a substantial
underestimation of VTE risk and non-adherence to guide-
lines for thromboprophylaxis in medical ICU patients
[14]. Additional co-morbidities such as stroke, acute heart
failure and respiratory insufficiency are highly prevalent
and contribute to a worse outcome [15,16].
Reliable data on the prevalence of VTE in patients
acutely admitted to a non-surgical ICU are however not
available and we aimed to overcome this lack of data.
Methods
Design
This was a prospective survey of daily clinical practice with
the prospective inclusion of consecutive ambulatory pa-
tients being acutely admitted to the non-surgical intensive-
care unit of the Karlsbad-Langensteinbach Hospital in
Germany. Ethical approval of the study was not necessary
due to the observational nature of the study. Patients pro-
vided written informed consent.
Patient population
Eligible patients had to have an age of at least 18 years and
an APACHE-II score of at least 10 which reflects a mortal-
ity risk of about 15%. Patients with known or suspected
VTE at hospital admission or prior recent hospitalization
were excluded. Predominant reasons for admission were
acute cardiovascular and pulmonary disorders. Among
them were several myocardial infarctions, decompensated
heart failure and pneumonias as the ICU focused on pa-
tient with acute cardiopulmonary diseases. No mechanic-
ally ventilated patient was included.
Variables obtained
All patients had a clinical workup at hospital admission
and the following variables were obtained: reason for ad-
mission, APÀCHE-II-score (see below), pharmacotherapy,
body weight and height, smoking status, use of compres-
sion stockings, co-morbidity, presence of clinical signs of
thrombosis (Payr and Homann sign, Lowenberg’s sign,
cyanosis, pain, and swelling). The following lab values
were determined: leukocytes, thrombocytes, erythrocytes,
quick/INR value, partial thromboplastin time, fibrinogen,
D-dimere and creatinine.
Detection of venous thrombo- and pulmonary embolism
Ultrasound compression sonography (ATL, HDIU 5000,
Philips Medical Systems GmbH, Hamburg, Germany)
was conducted in all patients within 24 hours after hos-
pital admission according to the EXCLAIM - protocol[17]. Investigators were to scan 10 pre-defined segments
of the femoral and popliteal veins including the peroneal
and tibial confluens (Figure 1). For the femoral veins,
static imaging was performed in the transverse plane
with the patient lying supine, while compression was ap-
plied at 0.5-1.0 cm intervals along the full length of the
vein. Compressed and uncompressed images were ob-
tained at the sites. For the popliteal veins, imaging was
performed with the patient in a sitting position with the
legs hanging over the edge of the examination table or
in case of inability to sit lying supine with the bed being
tilted 30% feets downwards, and compressed and un-
compressed images were obtained. In all patients with a
confirmed diagnosis of DVT or suspicion of PE thoracic
computer tomography (CT) was performed.
APACHE - Score
The APACHE-II (Acute Physiology And Chronic Health
Evaluation) score was used to determine the prognosis
(mortality) of patients [18-20]. It consists of an Acute
Physiologic Score (Table 1), indicating an increased
mortality risk with higher values. Age Points are added,
reflecting the age dependent increase in mortality. Finally
Chronic Health Score points are added for non-surgical
patients with pre-existing known organ insufficiency or
immunological incompetence.
Statistical methods
The analysis of data was performed with the statistical
software package SPSS for Windows. Descriptive statistical
analyses were performed. Frequencies were reported as
means ± standard deviation (SD). Differences were tested
by the Chi2-test or the Mann–Whitney U-Test for statis-
tical significance using an alpha of 0.05.
Results
Patient baseline characteristics
A total of 102 patients, 43 of them women (42.2%) with a
mean age of 71.4 ± 11.4 for men and 75.9 ± 14.0 years for
women, (p = 0.015 for gender difference) were included.
The mean APACHE-II score was 14. Roughly half of the
patients were pre-treated with aspirin (47.1%), 18.6% with
oral anticoagulation, 13.7% with clopidogrel and 6.9% with
any kind of heparin. Further patient characteristics and
risk factors are listed in Table 2.
DVT and PE incidence
A previously unknown thrombosis was detected in 8 pa-
tients (7.8%), 2 in women and 6 in men. Thrombus loca-
tion was femoropopliteal in 5 patients, iliacal in 2 and at
peroneal confluens in 1 patient. In five out of the eight
DVT patients pulmonary embolism (PE) was detected
upon CT lung scan (62.5% of DVT patients, 4.9% of all
Superﬁcial femoral vein 5 
External iliacal vein 2 
Posterior bial veins  0 
Common femoral vein 0 
Great saphenovein juncon 0 
Popliteal vein 0 
Peroneal conﬂuens 1 
Anterior bial veins 0 
n 
Figure 1 Localisation of venous thrombosis. Legend: n, number of patients with thrombosis at the localisation indicated.
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above the knee, twice iliacal and femoropopliteal.
Mean APACHE-II-Score of patients without DVT was
14.56, with DVT 14.38, which was slightly, but statisti-
cally not different. Two DVT patients had APACHE-II-
Scores of 10 and 11 respectively, the other DVT patients
scores of 15, 17, 20 and 21 respectively.Table 1 APACHE II Scoring
Acute physiologic score Aberration upwards
Points +4 +3 +2 +1
Temperature °C ≥ 41 39 – 40.9 38.5 - 3
MAP mmHg ≥ 160 130 - 159 110 - 129
Heart rate/min ≥ 180 140 - 179 110 - 139
Resp. rate/min ≥ 50 35 - 49 25 - 3
Oxygenation ≥ 500 350 - 499 200 - 349
Arterial pH ≥ 7.7 7.6 - 7.69 7.5 - 7
Sodium ≥ 180 160 - 179 155 - 159 150 - 1
Potassium ≥ 7 6.6 - 6.69 5.5 - 5
Creatinine mg/dl ≥ 3.5 2.0 - 3.4 1.5 - 1.9
Hematocrit % ≥ 60 50 - 59.9 46 - 4
Leucozytes ×103 ≥ 40 20 - 39.9 15 - 1
Glasgow Coma Scale (GCS)
Age points ≤ 44 45 - 54
Points 0 2Risk factors and laboratory values in patients with and
without DVT
The following established risk factors for VTE were tested:
1) smoking status, 2) immobility, 3) exsiccosis, 4) diabetes
mellitus, 5) coagulation disorders, 6) renal insufficiency
(Table 3). While there was a nominally increased relative
risk in those with smoking (RR 3.40), immobility (RR 2.50),Aberration downwards
0 +1 +2 +3 +4
8.9 36 - 38.4 34 - 35.9 32 - 33.9 30 - 31.9 ≤ 29.9
70 - 109 50 - 69 ≤ 49
70 - 109 55 - 69 40 - 54 ≤ 39
4 12 - 24 10 - 11 6 - 9 ≤ 5
< 200 | > 70 61 - 70 55 - 60 < 55
.59 7.33 - 7.49 7.25 - 7.32 7.15 - 7.24 < 7.15
54 130 - 149 120 - 129 111 - 119 ≤ 110
.59 3.5 - 5.4 3.0 - 3.4 2.5 - 2.9 ≤ 2.5
0.6 - 1.4 < 0.6
9.9 30 - 45.9 20 - 29.9 < 20
9.9 3 - 14.9 1 - 2.9 < 1
Points = 15 – actual GCS
55 - 64 65 - 74 ≥ 75
3 5 6
Table 2 Patient characteristics and risk factor prevalence







Male gender (n, %) 59 (57.8) 6 (75.0) 53 (56.4)
ASA (n, %) 48 (47.1) 3 (37.5) 45 (47.9)
Clopidogrel (n, %) 14 (13.7) 0 14 (17.9)
Marcumar (n, %) 19 (18.6) 0 19 (20.2)
Heparin (n, %) 7 (6.9) 1 (12.5) 6 (6.4)
Heart failure NYHA≥ II 68 (66.7) 0 68 (72.3)
Smoker 15 (14.7) 3 (37.5) 12 (12.8)
Immobility* (n, %) 54 (52.9) 6 (75.0) 48 (51.1)
Compressions stockings 14 (13.7) 1 (12.5) 13 (13.8)
Venous insufficiency 30 (29.4) 1 (12.5) 29 (30.9)
Renal insufficiency (n, %) 56 (54.9) 3 (37.5) 53 (56.4)
Malignancy 8 (n, %) 10 (9.8) 1 (12.5) 9 (9.6)
Exsiccosis (n, %) 21 (20.6) 2 (25.0) 19 (20.2)
Diabetes mellitus (n, %) 38 (37.3) 3 (37.5) 35 (37.2)
Legend: *Immobility was defined as not able to leave the room but to visit
toilet and bath in the room for more than 24 hours before hospital admission,
n, number; SD, standard deviation.
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risk in those with renal insufficiency (RR 0.49), confidence
intervals were too wide and only smoking became border-
line significant (p = 0.06).
The following laboratory values were tested: D-dimere,
leucocytes, C-reactive protein (CRP), partial thromboplastin
time (PTT), fibrinogen, thrombocytes, erythrocytes, quick,Table 3 Relative risk of traditional risk factors and
laboratory results in patients with vs. without DVT
RR [95% CI] P - value
Risk factors
Smoker (vs. nonsmoker) 3.40 (0.93-13.06) 0.06
Immobility (yes vs. no) 2.50 (0.53-11.79) 0.23
Exsiccosis (yes vs. no) 1.29 (0.28-5.92) 0.79
Diabetes mellitus (yes vs. no) 1.20 (0.29-5.09) 0.81
Renal insufficiency (yes vs. no) 0.49 (0.12-1.95) 0.30
Laboratory results
D-dimere (increased vs. normal) 3.49 (0.89-13.71) 0.58
CRP (increased vs. normal) 1.97 (0.42-9.27) 0.38
Leukocytes (increased vs. normal) 1.95 (0.49-7.73) 0.33
Fibrinogen (increased vs. normal) 1.5 (0.39-5.92) 0.55
PTT (increased vs. normal) 1.37 (0.30-6.27) 0.69
Erythrocytes (increased vs. normal) 0.17 (0.02-1.31) 0.05
Creatinine (increased vs. normal) 1.15 (0.29-4.53) 0.84
Thrombocytes (increased vs. normal) 1.03 (1.03-1.17) 0.28
Quick (decreased vs. normal) 0.44 (0.06-3.41) 0.41creatinin. No significant correlation was found for any of
the named laboratory values. The highest risk ratios were
found for D-dimere (RR 3.49), CRP (RR 1.97) and leuco-
cytes (RR 1.95).
Clinical follow up
6 out of 8 DVT patients (75%) were transferred from the
ICU to a general ward within a week after admission. One
DVT patient stayed at the intensive care unit for 14 days
and 1 patient died due to sepsis.
Discussion
The present prospective analysis is the first to report the
prevalence of DVT in acutely admitted non-surgical inten-
sive care unit patients in Germany. We investigated the
isolated prevalence rate within 24 hours after hospital ad-
mission not considering DVT incidence rates during the
ICU stay. We found a DVT prevalence of 7.8% with two
thirds of the DVT positive patients presenting additional
pulmonary embolism. The data are limited however by the
patient number that was found to be too low to conduct a
proper predictor analysis. This calls for a larger prospect-
ive survey to be conducted in this high risk patient group.
Prevalence of deep venous thrombosis
Limited data are available comparing VTE prevalence in
critical ill medical patients admitted to non-surgical inten-
sive care units with a variety of diseases, but not mechanic-
ally ventilated. Nevertheless these patients are frequent and
show an increased mortality risk. In general medical units
Lawall et al. [21] found in not critically ill patients a preva-
lence of 2.6% in medical patients, and Cheng [22] in a very
similar patient population a prevalence of 1.7%. Oger et al.
[23] reported (within 48 hours of hospital admission, in-
cluding incidence during hospitalization, without suspected
VTE at admission) an incidence of 5.5% (95% CI 3.1-9.5)
asymptomatic DVT using compression ultrasound and
17.8% (95% CI 0.0-12.7) among patients over 80 years. A
review by Crowther and Cook comprised data of several
studies and found DVT in 5 – 10% of critically ill patients
even if they receive unfractionated heparin for prophylaxis
[24]. The majority appeared clinically silent, a known
phenomenon from earlier studies [25-27]. One prospective
cohort study of twice weekly ultrasounds identified prox-
imal DVT during ICU stay in 25 out of 261 (9.6%) patients
[28]. The PROTECT trial tested dalteparin versus unfrac-
tionated heparin and found at intensive care unit patients
with a mean APACHE-II-Score of 21.5 a prevalence during
ICU stay of 5.5% [29]. This number represents a cumula-
tive prevalence and incidence in patients with ongoing
thromboprophylaxis. Hong et al. prospectively screened 90
ICU patients without prophylaxis and repeated admission
ultrasound 5–7 days after admission and 11.1% of patients
developed DVT [30]. Sud et al. [13] compared ultrasound
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medical-surgical ICU patients and found 85 proximal
DVT´s per 1000 patients. These numbers are comparable
to our findings.
Wells et al. found a high rate of false positive results
with careful clinical assessment for DVT only or in com-
bination with inflammation markers. They concluded
that this approach for DVT screening is not useful in
this patient group alone [31].
Older data reported by Hirsch et al. [25] for medical
ICU patients reported a DVT prevalence of 33%, but this
number included 8 months follow-up with ultrasound
screenings after discharge from MICU.
Prevalence of pulmonary embolism
We found accompanying pulmonary embolism (PE) in 5
patients (62.5% of DVT patients, 4.9% of all patients). This
rate is higher than in the literature described. There are
data showing silent PE in around 33% of DVT patients for
instance in the previously mentioned study by Lawall et al.
in internal medicine and in a recent study by Tzoran et al.,
who found in 33% of DVT patients additional PE [32]. But
those patients were no ICU patients, which are at higher
risk for DVT than general medical ward patients. A large
prospective multicenter Chinese trial found a prevalence
of DVT during medical ICU stay including a 90 day follow
up ultrasound and clinical examination of 7.3% with add-
itional PE in 0.5% and isolated PE in 2.1% [33]. Berlot
et al. retrospectively reviewed 600 autopsies and clinical
data of all patients who died at a mixed surgical and med-
ical ICU between 1996 and 2007 [34]. All patients received
prophylaxis with subcutaneous low-molecular weight hep-
arin. They found 13 confirmed PE, 20 not confirmed and
73 PE´s only discovered at the autopsy. The overall inci-
dence was 14.3%. Among all non-surgical co-morbidities
the presence of acute renal failure was associated with a
higher risk of missed diagnoses, which was also found with
a higher frequency in cases of septic shock.
Predictors of deep venous thrombosis
Several risk factors have been shown to be associated
with DVT. We found a tendency towards an increased
DVT risk for smoker, immobile, exsiccotic and diabetic
patients, but none reaching statistical significance. No
correlation was found in our study population for the
established risk factors age and gender or for laboratory
values. D-Dimer, leucocytes and CRP values showed a
tendency towards an increased risk. Unfortunately those
values are often increased anyway at hospital admission
resulting from the primary admission diagnosis. They
represent an ongoing unspecified inflammation process,
which is common in this patient population also without
a present DVT. A clinical use as DVT predicting risk
factor cannot be deduced from those results. No correlationbetween DVT prevalence and a high APACHE-II-Score
was found, but the incidence of DVT is quiet low for in-
terpretation of statistical correlations.
Limitations
The patient group under investigation reflects a heteroge-
neous medical patient group with a wide range of differing
thromboembolic risk constellations, predominantly acute
cardiovascular and pulmonary disorders without the need
for mechanical ventilation The strength of the study is
to have searched for predictors characterizing thrombo-
embolic risk in these patients, who are frequently treated
at ICUs but not extensively studied so far regarding throm-
bosis prevalence. As the patient numbers and resulting
DVT/PE prevalence rates were too low, no significant pre-
dictors were identified. A larger survey with higher num-
bers of DVT and PE patients is clearly needed to allow a
better patient characterisation using easy – available clin-
ical signs and laboratory values.
Conclusions
Our results show a rather high asymptomatic DVT
prevalence in acutely ill medical ICU admitted patients
with APACHE-II-score > 10 and a considerable amount
of accompanying pulmonary embolism. The studied pa-
tient group nonetheless lacks clear thromboembolic risk
characterisation as conventional risk factors, laboratory
values or the value of the APACHE-II-score seem to be
not sufficient. This result calls for further investigation
of a larger cohort of this special patient group. As long
as data are missing physicians in this clinical setting
should be aware of thromboembolic complications and
consider a general DVT screening at hospital admission
for this patient population.
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